How to Get Farxiga (Dapagliflozin) in North Carolina

Farxiga is the brand name for dapagliflozin, an oral SGLT2 inhibitor tablet made by AstraZeneca. It is prescription-only in every US state, including North Carolina; there is no over-the-counter version and no generic currently on the US market.

Getting a prescription in North Carolina is rarely the hard part: any physician, nurse practitioner, or physician assistant with NC prescriptive authority can write one, and licensed telehealth visits are permitted for SGLT2 inhibitors. The harder part is coverage. Dapagliflozin has three separate FDA-approved indications, type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease, and insurers, including NC Medicaid, apply different rules to each one. A prescription written for the wrong documented indication is the most common reason a fill gets delayed or denied.

What is established, what is plausible, and what needs verification

Established: Dapagliflozin is FDA-approved for type 2 diabetes, HFrEF, and CKD within specific eGFR ranges, and any NC-licensed prescriber can write for any of these indications without a specialty referral. Plausible but not something this article can quantify precisely: typical prior-authorization turnaround times, current cash prices, and savings-card discounts, because these change often and were not independently verified against a primary source for this draft. Not established here: any claim about a specific North Carolina insurer's current formulary tier or a specific NC Medicaid preferred-drug-list rule, those should be confirmed directly with the plan before a patient relies on them.

Who can prescribe Farxiga in North Carolina

Physicians (MD/DO), nurse practitioners, and physician assistants licensed in North Carolina can all prescribe dapagliflozin. North Carolina allows nurse practitioners to reach independent practice authority after a supervised practice period, after which they can prescribe SGLT2 inhibitors without a co-signing physician. Physician assistants prescribe under a supervisory arrangement with a licensed physician; that arrangement does not carve out SGLT2 inhibitors as restricted.

The FDA-approved prescribing information does not limit dapagliflozin to a specialty. Endocrinologists, cardiologists, nephrologists, and primary care clinicians all prescribe it based on the approved indications: type 2 diabetes; heart failure with reduced ejection fraction; and chronic kidney disease, generally within an eGFR range defined on the label. If you already have one of these diagnoses documented, your existing provider can typically add Farxiga during a standard visit without a specialist referral.

Does North Carolina allow telehealth prescribing for Farxiga?

Yes. North Carolina permits licensed telehealth prescribers to issue a dapagliflozin prescription after a synchronous video or audio evaluation; an in-person visit first is not required by the state. What a telehealth visit still needs is the same clinical information an in-person visit needs: your medical history, current medications, and lab results relevant to the indication being treated. If your labs are not recent, expect the prescriber to order them before writing the prescription rather than skip that step.

Several national telehealth platforms operating in North Carolina, including HealthRX.com, include SGLT2 inhibitors in their formularies. Typical turnaround from intake to a written prescription is commonly a few business days when labs are already on file, but exact timelines vary by platform and by whether prior authorization is needed, so treat any specific hour or day estimate as something to confirm with the platform at the time you book.

One practical advantage of telehealth in a state with rural coverage gaps: an electronic prescription can be routed to any pharmacy in North Carolina, including mail-order pharmacies licensed to ship into the state, which helps patients whose nearest specialty pharmacy is far away.

What labs are required before starting Farxiga

Baseline labs are standard practice before starting dapagliflozin, not a North Carolina-specific requirement. At minimum, most prescribers order serum creatinine with estimated glomerular filtration rate (eGFR), a basic metabolic panel to check electrolytes and kidney function, and hemoglobin A1c when the indication is type 2 diabetes. The FDA-approved kidney disease indication applies within an eGFR range defined on the product label; patients well below that range were not the population studied in the pivotal kidney trial, and the label reflects that boundary.

For heart failure, a documented ejection fraction from echocardiography and a natriuretic peptide level (BNP or NT-proBNP) support the clinical rationale and can simplify prior authorization. It's worth noting that the pivotal heart failure trial for dapagliflozin enrolled patients with chronic, stable HFrEF, not acute decompensated heart failure. A separate 2025 analysis specifically examining dapagliflozin's use around an acute heart failure hospitalization highlights that the acute setting is a distinct clinical question from the chronic outpatient indication the FDA approved (DAPA ACT HF-TIMI 68 lessons, 2025). If a prescriber is considering starting Farxiga during or immediately after a hospitalization, that is a judgment call outside the original chronic-HFrEF evidence base and worth an explicit conversation about what is and isn't established for that timing.

For CKD, a urine albumin-to-creatinine ratio (UACR) is commonly requested in addition to eGFR, since guideline bodies have extended SGLT2 inhibitor recommendations to patients with meaningful albuminuria regardless of diabetes status. Labs can be drawn at any commercial lab or hospital-affiliated draw station in North Carolina; results are commonly available within a day or two, though this varies by lab and test.

Will insurance cover Farxiga, and what does prior authorization require?

Most commercial insurers require prior authorization for dapagliflozin. In general, that means: a confirmed diagnosis matched to one of the three FDA-approved indications, documented baseline eGFR, evidence the patient meets label criteria, and a prescriber statement of medical necessity. For the diabetes indication specifically, many commercial plans ask for documentation of a metformin trial or intolerance before approving an SGLT2 inhibitor, consistent with how these drugs are typically positioned as second-line diabetes therapy.

This article does not have a verified, current source for any specific North Carolina insurer's formulary tier, exact prior-authorization turnaround time, or appeal success rate, and none of those numbers should be treated as reliable without checking directly with the plan. If a request is denied, prescribers can generally request a peer-to-peer review; documentation that ties the request explicitly to the FDA label criteria and to the relevant clinical guideline recommendation for that indication tends to strengthen an appeal.

AstraZeneca has historically offered a manufacturer savings card that reduces out-of-pocket cost for commercially insured patients; these programs typically exclude government insurance and have terms that change, so the current terms should be checked directly with the manufacturer or pharmacy at the time of fill rather than assumed from this article.

Does NC Medicaid cover Farxiga?

North Carolina Medicaid coverage for dapagliflozin depends heavily on indication, and Medicaid preferred-drug lists change. This article does not have a verified, dated source describing NC Medicaid's current preferred-drug-list status for dapagliflozin across each indication, so a Medicaid beneficiary or their prescriber should confirm current PDL status directly with NC Medicaid or the beneficiary's managed care plan rather than rely on a general claim here. Where a plan does not cover the diabetes indication, an exception or prior-authorization pathway tied to the heart failure or CKD indication may be worth pursuing if the patient's diagnosis actually supports it, since national heart failure guideline bodies have given SGLT2 inhibitors a strong recommendation for HFrEF regardless of diabetes status.

For patients who cannot obtain coverage through Medicaid, AstraZeneca's patient assistance program has historically provided the drug at no cost to qualifying low-income, uninsured, or underinsured patients; eligibility rules and income thresholds should be confirmed directly with the program before a patient counts on it.

503A compounded dapagliflozin: when it comes up and what it is not

North Carolina licenses 503A compounding pharmacies, which can prepare a patient-specific dapagliflozin formulation with a valid prescription. A 503A pharmacy compounds for an individual patient based on a prescriber's order, unlike a 503B outsourcing facility, which produces larger batches without patient-specific prescriptions.

Compounded dapagliflozin is not the same product as FDA-approved Farxiga. It has not gone through the FDA's bioequivalence review, and FDA guidance on compounding draws an explicit distinction between commercially available FDA-approved drugs and compounded preparations. Most prescribers default to the commercial product when it is available and affordable. A compounded version may come up when a patient needs an alternate dosage form the commercial tablet doesn't offer, or when cost is prohibitive and no assistance program applies, but that is a site-level judgment call, not a like-for-like substitute, and it should be discussed explicitly with the prescriber rather than assumed to be equivalent.

If pursuing a compounded product, confirm the pharmacy holds a valid North Carolina Board of Pharmacy compounding permit and follows USP 795 standards, and ask for a certificate of analysis for the active ingredient.

Filling and transferring the prescription in North Carolina

Chain pharmacies (CVS, Walgreens, Walmart), independent pharmacies, and mail-order pharmacies (such as major PBM-affiliated mail services) fill Farxiga prescriptions in North Carolina; stock availability varies by location, and most pharmacies can order it within a day or two if it isn't on the shelf.

Transferring a prescription to a North Carolina pharmacy from another state is a routine pharmacist-to-pharmacist process and generally does not require the patient to do anything beyond providing the originating pharmacy's information. Alternatively, a prescriber can simply send a new electronic prescription to the patient's preferred NC pharmacy, which avoids the transfer step entirely. Patients relocating to North Carolina should bring recent labs and a current medication list to their first local or telehealth appointment to avoid repeating baseline testing unnecessarily.

What Farxiga costs, and why an exact number here would be unreliable

Brand-name Farxiga is expensive without insurance, and manufacturer coupons, pharmacy discount programs, and patient assistance can meaningfully lower that cost for eligible patients. This draft does not have a dated, verified source for a specific current list price, cash price, or coupon price, and quoting an exact dollar figure without one would risk becoming stale or wrong the moment pricing changes. Before filling, patients should check the current cash price at their own pharmacy or a price-comparison tool, and ask the prescriber's office whether a manufacturer savings card or patient assistance program currently applies to their situation.

No generic dapagliflozin is available in the United States at this writing, and manufacturer patent protection has been reported to extend for several more years, though the exact expiration and any generic approval timeline should be confirmed against current FDA and patent-litigation sources rather than assumed.

The evidence behind the three approved indications

Three large randomized trials underlie dapagliflozin's FDA-approved indications, and it's worth understanding what each one actually tested, because insurers and Medicaid programs often ask for documentation tied to a specific indication rather than the drug in general.

A cardiovascular outcomes trial in patients with type 2 diabetes and either established atherosclerotic disease or multiple risk factors did not show a reduction in major adverse cardiovascular events overall, but did show a meaningful reduction in heart failure hospitalization. That finding is part of why interest in dapagliflozin shifted toward its cardiac and renal effects beyond glucose lowering.

A dedicated heart failure trial then tested dapagliflozin specifically in patients with heart failure and reduced ejection fraction, with or without diabetes, and found a meaningful reduction in the combined risk of cardiovascular death or worsening heart failure. The trial's investigators reported that the benefit appeared consistent whether or not patients had diabetes, which is the basis for treating dapagliflozin as a heart failure therapy in its own right rather than only a diabetes drug used off-label for the heart.

A separate CKD trial enrolled patients with reduced kidney function and elevated albuminuria and found a substantial reduction in the combined risk of sustained kidney function decline, kidney failure, or kidney/cardiovascular death; the trial was stopped early for benefit. Kidney disease guideline bodies subsequently extended a strong recommendation for SGLT2 inhibitors to CKD patients with significant albuminuria regardless of diabetes status.

Because the specific PMIDs and journal links associated with these trials in earlier drafts of this page could not be independently verified for this revision, exact hazard ratios and confidence intervals have been removed here pending confirmation against the primary literature and the current FDA label. A separate line of ongoing research is directly comparing outcomes between GLP-1 receptor agonists and SGLT2 inhibitors like dapagliflozin in people with diabetes; this is an active area of comparative-effectiveness research, and specific effect estimates from it should be checked against the original paper before being used to counsel an individual patient (comparative cardiovascular effectiveness analysis, 2026).

Safety, contraindications, and when to seek urgent care

Dapagliflozin carries labeled warnings that a North Carolina prescriber should discuss before starting the drug, including risk of diabetic ketoacidosis (which can occur even with normal or only mildly elevated blood glucose), volume depletion and low blood pressure, genital mycotic infections, and rare but serious necrotizing soft tissue infection of the perineum. Patients on dapagliflozin who develop nausea, vomiting, abdominal pain, unusual fatigue, or difficulty breathing should seek urgent evaluation rather than waiting for a routine follow-up, since these can be early signs of ketoacidosis even when blood sugar looks normal. This drug is not appropriate for individualized dosing decisions made from an article; dose and eligibility should be set by the prescribing clinician based on the patient's actual labs and history.

Verification checklist: what's stable versus what changes

Use this to separate facts that don't change month to month from facts that must be re-checked at the time a patient actually tries to fill or get coverage.

Stable, established by federal approval or clinical guidance (safe to treat as durable, but still confirm against the current FDA label):

• Dapagliflozin (Farxiga) is FDA-approved for type 2 diabetes, HFrEF, and CKD within a defined eGFR range.
• It is prescription-only nationwide; there is no OTC version.
• Baseline labs commonly required: eGFR/creatinine, BMP, A1c (diabetes), ejection fraction and natriuretic peptide (heart failure), UACR (CKD).
• Labeled risks include diabetic ketoacidosis, volume depletion, genital mycotic infection, and rare necrotizing soft tissue infection.
• North Carolina allows telehealth prescribing of SGLT2 inhibitors and permits MD/DO/NP/PA prescribing without a mandatory specialty referral.
• Compounded (503A) dapagliflozin is legally distinct from and not bioequivalent to the FDA-approved tablet.

Date-sensitive, must be re-verified at the time of use, not assumed from any article:

• Whether a specific commercial insurer or NC Medicaid MCO currently covers Farxiga for a given indication, and what prior-authorization documentation it requires today.
• NC Medicaid's current preferred-drug-list status for dapagliflozin.
• Current cash price, GoodRx-type discount price, and manufacturer savings card terms and eligibility.
• Whether a generic dapagliflozin has since been approved in the US.
• Typical prior-authorization or telehealth turnaround time at a specific plan or platform right now.
• Which specific NC-licensed pharmacies (chain, independent, or 503A) currently stock or will compound the medication.

If a fact falls in the second list, verify it directly with the insurer, NC Medicaid, the pharmacy, or the prescriber's office before relying on it, and note the date you confirmed it.

Frequently asked questions

References

1. U.S. Food and Drug Administration. Farxiga (dapagliflozin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202293s020lbl.pdf
2. U.S. Food and Drug Administration. Human drug compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
3. Dapagliflozin in acute heart failure: lessons from the DAPA ACT HF-TIMI 68 trial (2025). https://pubmed.ncbi.nlm.nih.gov/41354894/
4. Comparative cardiovascular effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors in diabetes mellitus (2026). https://pubmed.ncbi.nlm.nih.gov/41984016/

Prior-drafted citations to specific trial PMIDs (DECLARE-TIMI 58, DAPA-HF, DAPA-CKD) and to AHA/ACC/HFSA and KDIGO guideline links have been removed from this revision because they could not be independently verified against the correct source paper. The trial findings are described qualitatively above pending confirmation of the correct primary citations by editorial and medical review.